In summary, some studies fit with the general notion that FoxP3+ T cells suppress adaptive immune responses and led many groups to pursue strategies to deplete FoxP3+ T cells from patients or mouse with cancer as a means to enhance tumor immunity [53]–[55]. This evidence concerns the gene FOXP3 and neoplasm.